ACRS — Aclaris Therapeutics Share News
0.000.00%
- $532.87m
- $441.32m
- $7.83m
U.S. STOCKS ON THE MOVE-Vera Bradley, Shake Shack, 2seventy Bio
U.S. STOCKS ON THE MOVE-Citigroup, Regeneron, Ormat
U.S. STOCKS ON THE MOVE-Coya, AeroVironment, Cleveland-Cliffs
U.S. STOCKS ON THE MOVE-Nio, Aclaris, Nvidia
Aclaris surges after patent agreement with Sun Pharma
Brief: Aclaris Therapeutics Announces Patent License Agreement With Sun Pharma For Alopecia
U.S. RESEARCH ROUNDUP-Aclaris Therapeutics, Beauty Health Co, Vicarious Surgical
U.S. STOCKS ON THE MOVE-Boeing, Booking Holdings, Eli Lilly
U.S. STOCKS ON THE MOVE-Walmart, Lyft, CrowdStrike
Aclaris hits record low after scrapping rheumatoid arthritis drug development
U.S. STOCKS ON THE MOVE-HP, Digital World Acquisition, Guardant Health
Aclaris plunges after scrapping rheumatoid arthritis drug
Aclaris Therapeutics to stop development of rheumatoid arthritis drug (updated)
Aclaris Therapeutics to stop development of rheumatoid arthritis drug
Brief: Aclaris Therapeutics To Discontinue Further Development Of ATI-450 Program
Brief: Aclaris Therapeutics Sees Cash, Cash Equivalents And Marketable Securities As Of Sep. 30 Sufficient To Fund Operations Through End Of 2025
Aclaris Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Aclaris Therapeutics Announces Positive Results From Phase 1 Trial Of Ati-2138, An Investigational Oral Covalent Itk/Jak3 Inhibitor
Aclaris Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview